Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,973 INR
Change Today +10.90 / 0.56%
Volume 115.6K
DIVI On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

divi's laboratories ltd (DIVI) Snapshot

Open
1,966
Previous Close
1,962
Day High
1,995
Day Low
1,954
52 Week High
07/24/15 - 2,029
52 Week Low
08/12/14 - 1,448
Market Cap
261.8B
Average Volume 10 Days
134.1K
EPS TTM
64.15
Shares Outstanding
132.7M
EX-Date
08/6/15
P/E TM
30.7x
Dividend
20.00
Dividend Yield
1.01%
Current Stock Chart for DIVI'S LABORATORIES LTD (DIVI)

Related News

No related news articles were found.

divi's laboratories ltd (DIVI) Related Businessweek News

No Related Businessweek News Found

divi's laboratories ltd (DIVI) Details

Divi’s Laboratories Limited manufactures and sells active pharmaceutical ingredients (API) and intermediates for generics in India. The company also offers building blocks for peptides and nucleotides; carotenoids, such as apocarotenal, betacarotene, lycopene, astaxanthin, canthaxanthin, etc.; nutraceuticals; protected amino acids comprising BOC, FMOC, and CBZ; and novel ligands, including binol, binap, and others. The company also offers custom synthesis of API and advanced intermediates for discovery compounds to pharma companies. It also exports its products primarily to European and the American countries. The company was formerly known as Divi’s Research Center and changed its name to Divi’s Laboratories Limited in 1994. Divi’s Laboratories Limited was founded in 1990 and is headquartered in Hyderabad, India.

Founded in 1990

divi's laboratories ltd (DIVI) Top Compensated Officers

Chairman, Managing Director and Member of Cor...
Total Annual Compensation: 9.0M
President of Operations, Director of Operatio...
Total Annual Compensation: 7.8M
Executive Director and Member of Corporate So...
Total Annual Compensation: 8.4M
Director of Projects, Executive Director and ...
Total Annual Compensation: 7.8M
Compensation as of Fiscal Year 2014.

divi's laboratories ltd (DIVI) Key Developments

Divi's Laboratories Limited Recommends Dividend for the Year Ended March 31, 2015

Divi's Laboratories Limited announced that the Board of Directors of the Company at its meeting held on May 23, 2015 has recommended a dividend of 1000% i.e. INR 20/- per equity share of INR 2/- face value for the year ended March 31, 2015.

Divi's Laboratories Limited Announces Unaudited Standalone and Consolidated Earnings Results for Fourth Quarter and Full Year Ended March 31, 2015

Divi's Laboratories Limited announced unaudited standalone and consolidated earnings results for fourth quarter and full year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 8,146.9 million, total income from operations of INR 8,170.9 million, profit from operations before other income, finance costs and exceptional items of INR 2,825.3 million, profit from ordinary activities before tax of INR 2,825.3 million, net profit of INR 2,289.1 million or INR 17.25 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 7,380.1 million, total income from operations of INR 7,406.0 million, profit from operations before other income, finance costs and exceptional items of INR 2,449.0 million, profit from ordinary activities before tax of INR 2,449.0 million, net profit of INR 1,930.6 million or INR 14.54 per basic and diluted share after extraordinary items for the same quarter a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 30,723.0 million, total income from operations of INR 30,840.1 million, profit from operations before other income, finance costs and exceptional items of INR 10,671.8 million, profit from ordinary activities before tax of INR 10,671.8 million, net profit of INR 8,470.6 million or INR 63.82 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 25,071.8 million, total income from operations of INR 25,139.7 million, profit from operations before other income, finance costs and exceptional items of INR 10,086.4 million, profit from ordinary activities before tax of INR 10,086.4 million, net profit of INR 7,917.2 million or INR 59.65 per basic and diluted share after extraordinary items for the previous year. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 8,183.0 million, total income from operations of INR 8,207.0 million, profit from operations before other income, finance costs and exceptional items of INR 2,855.3 million, profit from ordinary activities before tax of INR 2,855.3 million, net profit of INR 2,314.7 million or INR 17.4 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 7,476.2 million, total income from operations of INR 7,502.1 million, profit from operations before other income, finance costs and exceptional items of INR 2,489.3 million, profit from ordinary activities before tax of INR 2,489.3 million, net profit of INR 1,964.3 million or INR 14.8 per basic and diluted share after extraordinary items for the same quarter a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 31,032.3 million, total income from operations of INR 31,149.4 million, profit from operations before other income, finance costs and exceptional items of INR 10,720.8 million, profit from ordinary activities before tax of INR 10,720.8 million, net profit of INR 8,515.2 million or INR 64.15 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 25,253.5 million, total income from operations of INR 25,321.4 million, profit from operations before other income, finance costs and exceptional items of INR 9,909.2 million, profit from ordinary activities before tax of INR 9,909.2 million, net profit of INR 7,733.4 million or INR 58.26 per basic and diluted share after extraordinary items for the previous year.

Divi's Laboratories Limited to Report Fiscal Year 2015 Results on May 23, 2015

Divi's Laboratories Limited announced that they will report fiscal year 2015 results on May 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIVI:IN 1,972.50 INR +10.90

DIVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 462.20 INR +4.80
Dishman Pharmaceuticals & Chemicals Ltd 205.35 INR -4.60
Piramal Enterprises Ltd 901.05 INR -19.15
Shasun Pharmaceuticals Ltd 380.75 INR -8.20
Torrent Pharmaceuticals Ltd 1,426 INR -15.25
View Industry Companies
 

Industry Analysis

DIVI

Industry Average

Valuation DIVI Industry Range
Price/Earnings 29.8x
Price/Sales 8.2x
Price/Book 7.3x
Price/Cash Flow 25.7x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIVI'S LABORATORIES LTD, please visit www.divislaboratories.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.